483 related articles for article (PubMed ID: 30453950)
1. Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
Tenorio-Jiménez C; Martínez-Ramírez MJ; Tercero-Lozano M; Arraiza-Irigoyen C; Del Castillo-Codes I; Olza J; Plaza-Díaz J; Fontana L; Migueles JH; Olivares M; Gil Á; Gomez-Llorente C
BMC Complement Altern Med; 2018 Nov; 18(1):306. PubMed ID: 30453950
[TBL] [Abstract][Full Text] [Related]
2.
Tenorio-Jiménez C; Martínez-Ramírez MJ; Del Castillo-Codes I; Arraiza-Irigoyen C; Tercero-Lozano M; Camacho J; Chueca N; García F; Olza J; Plaza-Díaz J; Fontana L; Olivares M; Gil Á; Gómez-Llorente C
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31370223
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled Trial.
Kong XJ; Liu K; Zhuang P; Tian R; Liu S; Clairmont C; Lin X; Sherman H; Zhu J; Wang Y; Fong M; Li A; Wang BK; Wang J; Yu Z; Shen C; Cui X; Cao H; Du T; Wan G; Cao X
Probiotics Antimicrob Proteins; 2021 Dec; 13(6):1508-1520. PubMed ID: 34115318
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial.
Mobini R; Tremaroli V; Ståhlman M; Karlsson F; Levin M; Ljungberg M; Sohlin M; Bertéus Forslund H; Perkins R; Bäckhed F; Jansson PA
Diabetes Obes Metab; 2017 Apr; 19(4):579-589. PubMed ID: 28009106
[TBL] [Abstract][Full Text] [Related]
5. Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity.
Oh JH; Schueler KL; Stapleton DS; Alexander LM; Yen CE; Keller MP; Attie AD; van Pijkeren JP
mSphere; 2020 Jun; 5(3):. PubMed ID: 32581074
[TBL] [Abstract][Full Text] [Related]
6. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread.
Dommels YE; Kemperman RA; Zebregs YE; Draaisma RB; Jol A; Wolvers DA; Vaughan EE; Albers R
Appl Environ Microbiol; 2009 Oct; 75(19):6198-204. PubMed ID: 19684171
[TBL] [Abstract][Full Text] [Related]
7. Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial.
Jørgensen MR; Keller MK; Kragelund C; Hamberg K; Ericson D; Nielsen CH; Twetman S
Acta Odontol Scand; 2016 Jul; 74(5):399-404. PubMed ID: 27104984
[TBL] [Abstract][Full Text] [Related]
8. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study.
del Campo R; Garriga M; Pérez-Aragón A; Guallarte P; Lamas A; Máiz L; Bayón C; Roy G; Cantón R; Zamora J; Baquero F; Suárez L
J Cyst Fibros; 2014 Dec; 13(6):716-22. PubMed ID: 24636808
[TBL] [Abstract][Full Text] [Related]
9.
Zheng F; Wang Z; Stanton C; Ross RP; Zhao J; Zhang H; Yang B; Chen W
Food Funct; 2021 May; 12(9):3919-3930. PubMed ID: 33977963
[TBL] [Abstract][Full Text] [Related]
10. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice.
Fåk F; Bäckhed F
PLoS One; 2012; 7(10):e46837. PubMed ID: 23056479
[TBL] [Abstract][Full Text] [Related]
11. The effect of orally administered probiotic Lactobacillus reuteri-containing tablets in peri-implant mucositis: a double-blind randomized controlled trial.
Flichy-Fernández AJ; Ata-Ali J; Alegre-Domingo T; Candel-Martí E; Ata-Ali F; Palacio JR; Peñarrocha-Diago M
J Periodontal Res; 2015 Dec; 50(6):775-85. PubMed ID: 25712760
[TBL] [Abstract][Full Text] [Related]
12. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Fatheree NY; Liu Y; Taylor CM; Hoang TK; Cai C; Rahbar MH; Hessabi M; Ferris M; McMurtry V; Wong C; Vu T; Dancsak T; Wang T; Gleason W; Bandla V; Navarro F; Tran DQ; Rhoads JM
J Pediatr; 2017 Dec; 191():170-178.e2. PubMed ID: 28969890
[TBL] [Abstract][Full Text] [Related]
13. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.
Simon MC; Strassburger K; Nowotny B; Kolb H; Nowotny P; Burkart V; Zivehe F; Hwang JH; Stehle P; Pacini G; Hartmann B; Holst JJ; MacKenzie C; Bindels LB; Martinez I; Walter J; Henrich B; Schloot NC; Roden M
Diabetes Care; 2015 Oct; 38(10):1827-34. PubMed ID: 26084343
[TBL] [Abstract][Full Text] [Related]
14. Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic.
Nation ML; Dunne EM; Joseph SJ; Mensah FK; Sung V; Satzke C; Tang MLK
Sci Rep; 2017 Nov; 7(1):15047. PubMed ID: 29118383
[TBL] [Abstract][Full Text] [Related]
15. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol.
Silva-Sperb AS; Moraes HA; de Moura BC; Alves BC; Bruch-Bertani JP; Azevedo VZ; Dall'Alba V
Trials; 2019 Oct; 20(1):580. PubMed ID: 31601229
[TBL] [Abstract][Full Text] [Related]
16. Effects of
Martí M; Spreckels JE; Ranasinghe PD; Wejryd E; Marchini G; Sverremark-Ekström E; Jenmalm MC; Abrahamsson T
Cell Rep Med; 2021 Mar; 2(3):100206. PubMed ID: 33763652
[TBL] [Abstract][Full Text] [Related]
17. The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial.
Kassaian N; Aminorroaya A; Feizi A; Jafari P; Amini M
Trials; 2017 Mar; 18(1):148. PubMed ID: 28356129
[TBL] [Abstract][Full Text] [Related]
18. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
19. Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial.
Romani Vestman N; Chen T; Lif Holgerson P; Öhman C; Johansson I
PLoS One; 2015; 10(5):e0125812. PubMed ID: 25946126
[TBL] [Abstract][Full Text] [Related]
20. Presence of Lactobacillus reuteri in saliva coincide with higher salivary IgA in young adults after intake of probiotic lozenges.
Braathen G; Ingildsen V; Twetman S; Ericson D; Jørgensen MR
Benef Microbes; 2017 Feb; 8(1):17-22. PubMed ID: 27873545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
